Eagle’s Eye View: Beta-Blocker vs. Calcium-Channel Blocker in HCM
In this week’s View, Dr. Eagle looks at the differential effect of bisoprolol versus verapamil in nonobstructive hypertrophic cardiomyopathy (HCM) treatment. He then explores lower heart failure (HF) hospitalization risk in patients with type 2 diabetes, comparing GLP-1RAs to DPP-4 inhibitors and similar outcomes with SGLT-2 inhibitors. Dr. Eagle then examines the use of shared decision-making and decision aids in percutaneous left atrial appendage occlusion (LAAO). Finally, the iModern trial, which compares immediate percutaneous coronary intervention (PCI) guided by instantaneous wave-free ratio (iFR) and deferred PCI guided by cardiac stress magnetic resonance imaging (MRI) in patients with STEMI and multivessel disease, is discussed.
X Links:
- Kim Eagle, MD, MACC keaglemd
Clinical Topics: Heart Failure and Cardiomyopathies, Acute Heart Failure, Acute Coronary Syndromes
Keywords: Exercise Tolerance, Calcium Channel Blockers, Cardiomyopathy, Hypertrophic, Bisoprolol, Cardiomyopathies, Heart Failure, Verapamil, Centers for Medicare and Medicaid Services, U.S., National Cardiovascular Data Registries, Decision Support Techniques, Registries, LAAO Registry, Atrial Appendage, Documentation, Sodium-Glucose Transporter 2 Inhibitors, Glucagon-Like Peptide 1, Dipeptidyl-Peptidase IV Inhibitors, Diabetes Mellitus, Type 2, Metabolic Diseases, EaglesEyeView
